New Guided VCTE™ technology will
increase efficiency, automation and standardization to make liver
scanning seamless for all healthcare providers
PARIS, May 21, 2024 /PRNewswire/ -- Liver disease
now accounts for two million deaths per year worldwide. This figure
is expected to rise as obesity rates continue to climb globally.
Responding to the dire need for enhanced liver health
management, Echosens, the leader in liver health, is proud to
announce its new next-generation FibroScan® with Guided
Vibration-Controlled Transient Elastography (VCTE)™
technology is now available globally. First launched in
the United States in February,
this next-generation FibroScan® is an essential tool in
the battle against liver disease and meets the urgent need for
precise, efficient, and non-invasive liver assessment, delivering
on the needs of healthcare professionals at the forefront of
patient care.
Laurent Sandrin, founder and
Chief Science & Innovation Officer of Echosens, underscores the
crucial role of healthcare professionals in increasing screening
rates, with three in 10 people globally at risk for liver disease.
"Given the projected surge in liver disease cases, it is imperative
to bolster screening rates for early detection. Our
next-generation FibroScan®, featuring our patented
Guided VCTE™ technology, is designed to be an
indispensable and efficient tool for both diagnosis and monitoring.
We are committed to elevating the liver care standards for all
patients, including obese patients, where assessments were
previously challenging. We recognize and value the pivotal role of
healthcare professionals in this process."
Guided VCTE™ leverages Echosens' diagnostic
expertise, providing precise liver stiffness and steatosis
measurements. Healthcare professionals can use this sophisticated,
user-friendly technology for rapid, non-invasive evaluations across
varied patient demographics, improving diagnostic speed and
workflow.
"Our goal is to increase the accessibility of liver assessments,
and we believe that empowering healthcare providers with a
technology that is accurate, simple, and fast is the key. As global
rates of metabolic dysfunction-associated fatty liver disease
(MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH)
grow, our commitment to innovation and equipping healthcare
providers with world-class technology is emboldened," continued
Sandrin.
Patients benefit from quicker and more efficient evaluations,
reducing anxiety and discomfort. Immediate results also lead to
more productive consultations at the point of care, minimizing
decision-making and treatment-initiation delays.
"One of the standout benefits of the next-generation
FibroScan® enhancement is the improved quality and
consistency of the results obtained. By incorporating Guided
VCTE™, as healthcare providers, we can achieve more
accurate and reliable assessments of liver stiffness, leading to
improved patient diagnostic outcomes," said Louise Campbell, Nurse Specialist and Clinical
Director at Tawazun Health. "This is particularly important in the
context of liver health and disease, as early detection and
accurate monitoring are essential for optimal patient care."
Key features of Guided VCTE™ include:
- Increased efficiency: Taking only four minutes for a
full scan, the rapid and efficient nature of Guided
VCTE™ makes it an ideal solution for busy healthcare
environments, improving workflow and increasing accessibility to
liver health assessments.
- Improved guidance: Guided VCTE™ introduces
two new visual indicators – one for liver stiffness and one for
CAP™ – to aid the operator in quickly identifying the
optimal measurement location.
- Simplified scanning: A refreshed, easily navigable new
user interface enables a streamlined workflow and learning curve
for all operators. A new efficiency feature, AutoScan, also allows
operators to capture 10 valid measurements through a single click,
increasing efficiency without compromising quality.
Guided VCTE™ represents the latest milestone in
Echosens' ongoing commitment to product innovation and evolution.
As the global leader in liver health, Echosens empowers healthcare
professionals with a gold-standard, non-invasive solution for
comprehensive liver management. This advancement simplifies
diagnosis and disease management by making liver assessments more
accessible and seamlessly integrated into practices.
Guided VCTE™ provides unparalleled accuracy and ease
of use. As the first connected devices in the FibroScan®
range, it introduces simplified cloud-based reporting and multiple
features through the upcoming Liver Health Management Platform, an
innovative cloud-based solution to enhance patient management
across the care continuum. Once again, after years of maintaining
an exceptional track record in innovation, Echosens sets itself
apart from other imaging techniques, reaffirming its leadership
position in the industry.
For more information on Echosens' liver health solutions, visit
echosens.com, and for information on the Guided VCTE™, please visit
here.
About Echosens
Pioneer in its field, Echosens, significantly changed the
practice of liver assessment with FibroScan®, the
non-invasive solution for comprehensive management of liver health.
FibroScan® is recognized worldwide and validated by over
4,200 peer-reviewed publications and 180+ international guidelines.
Echosens has made FibroScan® available in over 127
countries, enabling millions of liver examinations
worldwide. https://www.echosens.com/
Logo -
https://mma.prnewswire.com/media/2370966/Logo_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/transforming-liver-health-echosens-next-generation-fibroscan-now-available-worldwide-302151713.html